Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Exact Sciences Corporation (EXAS : NSDQ)

• Company Description    Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The company has developed an accurate, non-invasive, patient-friendly screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. The company is currently working on the development of additional tests for other types of cancer, with the goal of becoming a leader in cancer screening and diagnostics. Exact Sciences currently has two of the brands in cancer diagnostics, Cologuard and Oncotype DX. Cologuard Test: This is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Oncotype DX: Genomic Health's first product, the 21-gene Oncotype DX breast cancer test is used to predict the likelihood of cancer recurrence, patient survival within 10 years of diagnosis and chemotherapy benefit for early-stage patients. Number of Employees: 7,000

• Price / Volume Information    Yesterday's Closing Price: $51.63 Daily Weekly Monthly 20 Day Moving Average: 2,628,700 shares Shares Outstanding: 188.64 (millions) Market Capitalization: $9,739.36 (millions) Beta: 0.92 52 Week High: $72.83 52 Week Low: $39.97 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 16.15% 10.07% 12 Week 4.70% 13.12% Year To Date -8.12% -4.52%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5505 ENDEAVOR LANE - MADISON,WI 53719 USA ph: 608-535-8815 fax: 608-284-5701 investorrelations@exactsciences.com http://www.exactsciences.com

• General Corporate Information    Officers Kevin T. Conroy - President and Chief Executive Officer Aaron Bloomer - Executive Vice President and Chief Financial Offic Mike Barber - Director Paul Clancy - Director D. Scott Coward - Director Peer Information Exact Sciences Corporation (CORR.) Exact Sciences Corporation (RSPI) Exact Sciences Corporation (CGXP) Exact Sciences Corporation (BGEN) Exact Sciences Corporation (GTBP) Exact Sciences Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 30063P105 SIC: 8071 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 07/30/25 Share - Related Items Shares Outstanding: 188.64 Most Recent Split Date: (:1) Beta: 0.92 Market Capitalization: $9,739.36 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.08 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.14 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 29.27% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/30/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.06 Price/Cash Flow: 9.17 Price / Sales: 3.44 EPS Growth vs. Year Ago Period: 58.00% vs. Previous Quarter: -250.00% Sales Growth vs. Year Ago Period: 10.86% vs. Previous Quarter: -0.93% ROE 03/31/25 - -3.75 12/31/24 - -5.29 09/30/24 - -6.17 ROA 03/31/25 - -1.68 12/31/24 - -2.45 09/30/24 - -2.98 Current Ratio 03/31/25 - 2.73 12/31/24 - 2.15 09/30/24 - 2.12 Quick Ratio 03/31/25 - 2.38 12/31/24 - 1.92 09/30/24 - 1.93 Operating Margin 03/31/25 - -3.71 12/31/24 - -5.72 09/30/24 - -7.27 Net Margin 03/31/25 - -36.06 12/31/24 - -37.29 09/30/24 - -7.95 Pre-Tax Margin 03/31/25 - -36.38 12/31/24 - -37.56 09/30/24 - -7.82 Book Value 03/31/25 - 12.71 12/31/24 - 12.98 09/30/24 - 17.38 Inventory Turnover 03/31/25 - 5.67 12/31/24 - 6.05 09/30/24 - 6.40 Debt-to-Equity 03/31/25 - 0.97 12/31/24 - 0.97 09/30/24 - 0.72 Debt-to-Capital 03/31/25 - 49.21 12/31/24 - 49.14 09/30/24 - 41.94

Powered by Zacks Investment Research ©